- medical research
CORVIA MEDICAL ANNOUNCES RANDOMIZATION OF FIRST PATIENT IN THE RESPONDER-HF CONFIRMATORY TRIAL
TEWKSBURY, Mass., Dec. 6, 2022 /PRNewswire/ -- Corvia Medical, Inc., a company dedicated to transforming the treatment of heart failure (HF), announced the first patient has been randomized in RESPONDER-HF, a global confirmatory trial of the Corvia Atrial Shunt in heart failure patients with preserved (HFpEF) or mildly reduced (HFmrEF) ejection fraction. The first patient was enrolled and randomized by Scott Lilly, M.D., Interventional...
Read more